Pharming announces positive results of Phase II/III pivotal clinical study of leniolisib for the treatment of activated PI3K delta syndrome

February 2, 2022 at 7:00 AM CET
Pharming Group announces positive results from the pivotal Phase II/III blinded randomized, placebo-controlled registration-enabling study of leniolisib for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) also known as PASLI (p110δ-activating mutation causing senescent T cells, lymphadenopathy, and immunodeficiency).

The company will hold an analyst conference call tomorrow, Thursday 3 February, at 14:00CET/08:00ET.

Conference call dial in information
Thursday February 3, 2022 14:00CET/08:00ET
Please note, the company will only take questions from dial-in attendees.
Dial in details: United Kingdom 0800 640 6441
United Kingdom (Local) 020 3936 2999
Netherlands (Local) 085 888 7233
United States 1 855 9796 654
United States (Local) 1 646 664 1960
Access code: 871929

Webcast link: https://webcast.openbriefing.com/pharming-22/